WO2005077373A3 - Treatment of gastro-esophageal reflux disease (gerd) - Google Patents

Treatment of gastro-esophageal reflux disease (gerd) Download PDF

Info

Publication number
WO2005077373A3
WO2005077373A3 PCT/US2005/000335 US2005000335W WO2005077373A3 WO 2005077373 A3 WO2005077373 A3 WO 2005077373A3 US 2005000335 W US2005000335 W US 2005000335W WO 2005077373 A3 WO2005077373 A3 WO 2005077373A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastro
treatment
reflux disease
gerd
esophageal reflux
Prior art date
Application number
PCT/US2005/000335
Other languages
French (fr)
Other versions
WO2005077373A2 (en
Inventor
Anders Lehmann
Jan Mattsson
Karolina Nilsson
Original Assignee
Astrazeneca Ab
Nps Pharma Inc
Anders Lehmann
Jan Mattsson
Karolina Nilsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Nps Pharma Inc, Anders Lehmann, Jan Mattsson, Karolina Nilsson filed Critical Astrazeneca Ab
Publication of WO2005077373A2 publication Critical patent/WO2005077373A2/en
Publication of WO2005077373A3 publication Critical patent/WO2005077373A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of a compound of formula (I) for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of compounds of formula (I) for the treatment of gastro-esophageal reflux disease.
PCT/US2005/000335 2004-02-03 2005-01-07 Treatment of gastro-esophageal reflux disease (gerd) WO2005077373A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54105504P 2004-02-03 2004-02-03
US60/541,055 2004-02-03

Publications (2)

Publication Number Publication Date
WO2005077373A2 WO2005077373A2 (en) 2005-08-25
WO2005077373A3 true WO2005077373A3 (en) 2005-11-24

Family

ID=34860187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/000335 WO2005077373A2 (en) 2004-02-03 2005-01-07 Treatment of gastro-esophageal reflux disease (gerd)

Country Status (1)

Country Link
WO (1) WO2005077373A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity
US9278962B2 (en) 2011-04-22 2016-03-08 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2624610T3 (en) 2003-04-11 2017-07-17 Ptc Therapeutics, Inc. Compounds of 1,2,4-oxadiazole benzoic acid and their use for nonsense suppression and disease treatment
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
EP2441763A1 (en) 2005-07-26 2012-04-18 Glaxo Group Limited Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders
TW200800946A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Substituted piperazines as metabotropic glutamate receptor antagonists
TW200800204A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Bicyclic piperazines as metabotropic glutatmate receptor antagonists
CN101505739A (en) 2006-03-30 2009-08-12 Ptc医疗公司 Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
PL2041088T3 (en) 2006-06-28 2014-07-31 Amgen Inc Glycine transporter-1 inhibitors
DE602007006019D1 (en) 2006-06-28 2010-06-02 Glaxo Group Ltd PIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OF DISEASES MEDIATED BY THE GPR38 RECEPTOR
EP2081905B1 (en) 2006-07-28 2012-09-12 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
WO2008042571A2 (en) 2006-09-29 2008-04-10 Smithkline Beecham Corporation Substituted indole compounds
EP2727910B1 (en) 2007-09-21 2016-03-16 Array Biopharma, Inc. Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators
JP5492092B2 (en) 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
US8765743B2 (en) 2008-06-05 2014-07-01 Glaxosmithkline Intellectual Property Development Limited Compounds
ES2526966T3 (en) 2008-06-05 2015-01-19 Glaxo Group Limited Novel compounds
US8658635B2 (en) 2008-06-05 2014-02-25 Glaxosmithkline Intellectual Property Development Limited Benzpyrazol derivatives as inhibitors of PI3 kinases
EP2288607B1 (en) 2008-06-09 2014-09-24 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
JP5749162B2 (en) 2008-07-10 2015-07-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sulfone compounds that modulate the CB2 receptor
AU2009271003A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
AU2009271019A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
MX2011001090A (en) 2008-07-28 2011-03-15 Gilead Sciences Inc Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds.
BRPI0919172A2 (en) 2008-09-25 2015-12-15 Boehringer Ingelheim Int compounds which selectively modulate the cb2 receptor
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8889670B2 (en) 2009-02-18 2014-11-18 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the CB2 receptor
JP5656880B2 (en) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 4-oxadiazol-2-yl-indazole as an inhibitor of PI3 kinase
KR101771193B1 (en) 2009-04-30 2017-09-05 글락소 그룹 리미티드 Oxazole substituted indazoles as pi3-kinase inhibitors
AU2010256360A1 (en) 2009-06-05 2012-01-12 Astrazeneca Ab Aminopyrrolidinone derivatives and uses thereof
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
BRPI1010884A2 (en) 2009-06-08 2016-03-15 Gilead Sciences Inc hdac alkanoylamino benzamide aniline inhibitors compound
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (en) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
WO2011037795A1 (en) 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
JP5748777B2 (en) 2010-02-02 2015-07-15 ノバルティス アーゲー Cyclohexylamide derivatives as CRF receptor antagonists
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
EP2595959B1 (en) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
CN112500338A (en) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 Compounds and their use for modulating hemoglobin
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN105518005B (en) 2013-07-02 2018-07-20 百时美施贵宝公司 Tricyclic pyridine-carboxamides derivatives as ROCK inhibitor
CN105492444B (en) 2013-07-02 2018-09-07 百时美施贵宝公司 Tricyclic pyridine-carboxamides derivatives as ROCK inhibitor
EA030631B1 (en) 2013-07-31 2018-09-28 Новартис Аг 1,4-disubstituted pyridazine quinoline derivatives and methods for treating smn-deficiency-related conditions
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
CN106455571A (en) 2014-03-06 2017-02-22 Ptc医疗公司 Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
CA2952862A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
AU2015367531B2 (en) 2014-12-17 2020-04-30 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (en) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
CA2971855A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
AU2016297886B2 (en) 2015-07-24 2020-12-10 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing CFTR activity
JP2018531924A (en) 2015-09-24 2018-11-01 ファイザー・インク Tetrahydropyrano [3,4-D] [1,3] oxazine derivatives and their use as BACE inhibitors
JP6929276B2 (en) 2015-10-06 2021-09-01 プロテオステイシス セラピューティクス，インコーポレイテッド Compounds, pharmaceutically acceptable salts or stereoisomers thereof and pharmaceutical compositions
AR106530A1 (en) 2015-10-30 2018-01-24 Ptc Therapeutics Inc METHODS TO TREAT EPILEPSY
KR102448404B1 (en) 2016-04-07 2022-09-27 프로테오스타시스 테라퓨틱스, 인크. Silicon atom-containing ivacarpter analogues
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
ES2921432T3 (en) 2016-06-13 2022-08-25 Gilead Sciences Inc Azetidine derivatives as modulators of FXR (NR1H4)
US10899751B2 (en) 2016-06-21 2021-01-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
GB201610867D0 (en) 2016-06-22 2016-08-03 King's College London Crystalline forms of a therapeutic compound and processes for their preparation
ES2927019T3 (en) 2017-03-28 2022-11-02 Gilead Sciences Inc Therapeutic combinations for the treatment of liver diseases
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
WO2020072964A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
DK3911647T3 (en) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazole compound as FXR agonist and pharmaceutical compositions comprising such
CU20210065A7 (en) 2019-01-31 2022-04-07 Pfizer 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS THAT HAVE INHIBITORY ACTIVITY ON CDK2
CN113439078B (en) 2019-02-19 2024-04-23 吉利德科学公司 Solid forms of FXR agonists

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476128A (en) * 1980-03-01 1984-10-09 Mitsuitoatsu Chemicals, Inc. 2-Substituted thiazolyl-piperazine compounds, process for preparation thereof and utilizations thereof _
EP0328200A1 (en) * 1988-02-12 1989-08-16 Merck Sharp & Dohme Ltd. Five-membered ring systems with bonded azacyclic ring substituents
EP0438230A2 (en) * 1990-01-17 1991-07-24 MERCK SHARP & DOHME LTD. Indole-substituted five-membered heteroaromatic compounds
WO1993002677A1 (en) * 1991-08-03 1993-02-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO2002010140A2 (en) * 2000-08-01 2002-02-07 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Imidazolyl derivatives
WO2004014370A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476128A (en) * 1980-03-01 1984-10-09 Mitsuitoatsu Chemicals, Inc. 2-Substituted thiazolyl-piperazine compounds, process for preparation thereof and utilizations thereof _
EP0328200A1 (en) * 1988-02-12 1989-08-16 Merck Sharp & Dohme Ltd. Five-membered ring systems with bonded azacyclic ring substituents
EP0438230A2 (en) * 1990-01-17 1991-07-24 MERCK SHARP & DOHME LTD. Indole-substituted five-membered heteroaromatic compounds
WO1993002677A1 (en) * 1991-08-03 1993-02-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO2002010140A2 (en) * 2000-08-01 2002-02-07 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Imidazolyl derivatives
WO2004014370A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity
US9278962B2 (en) 2011-04-22 2016-03-08 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use

Also Published As

Publication number Publication date
WO2005077373A2 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
WO2005077373A3 (en) Treatment of gastro-esophageal reflux disease (gerd)
WO2005077368A3 (en) Treatment of gastro-esophageal reflux disease (gerd)
WO2005074642A3 (en) Chemical compounds
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2006133147A3 (en) Organic compounds
HK1075833A1 (en) Use of mglur5 antagonists for the treatment of gerd
WO2009121033A3 (en) Substituted nitrogen heterocycles and synthesis and uses thereof
WO2006135640A3 (en) Process for the synthesis of organic compounds
HK1165426A1 (en) Methods of synthesizing pharmaceutical salts of a factor xa inhibitor xa
WO2007085895A3 (en) Fap inhibitors
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
WO2007105058A8 (en) Pyrazole compounds
WO2008092954A8 (en) Polymorphic forms of a macrocyclic inhibitor of hcv
EA200601358A1 (en) NEW CHEMAZ INHIBITORS
EA200870117A1 (en) AZAINDOL INHIBITORS AURORA-KINAZ
PL1720802T3 (en) Oxidation of organic compounds at high ph
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2007003934A3 (en) 17beta-hydr0xyster0id dehydrogenase type 3 (17beta-hsd3 ) inhibitors
JP2012501296A5 (en)
MX2009010893A (en) Xanthine compounds having a positive allosteric gabab receptor modulator effect.
WO2009098458A3 (en) Difluorobiphenylamide derivatives for the treatment of ocular hypertension
SE0401653D0 (en) New compounds
DE602007011231D1 (en) TRIAZOLONDERIVAT
EA200600330A1 (en) SUBSTITUTED IMIDAZOPIRIMIDINES FOR PREVENTION AND TREATMENT OF CANCER
WO2007054776A3 (en) Stilbene like compounds as novel hdac inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase